Shots:

• Fresenius Kabi discusses the US FDA’s review about the prospects of pegfilgrastim biosimilar product and the commercialization of the product
• The company also plans for MSB11456 (biosimilar, tocilizumab) based on the recent positive results which are used for the treatment of RA referencing Actemra
• The company is awaiting the completion of the US FDA’s inspection to enable the completion of the Stimufend application review. The company has scaled the pegfilgrastim biosimilars in the EU

Ref: Fresenius Kabi | Image: Fresenius Kabi